Patents by Inventor Oleksandr Balakin
Oleksandr Balakin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240173350Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.Type: ApplicationFiled: August 28, 2023Publication date: May 30, 2024Applicant: Vector Vitale IP LLCInventors: Peter NOVAK, Max TEMNIK, Oleksandr BALAKIN
-
Patent number: 11986541Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.Type: GrantFiled: August 9, 2023Date of Patent: May 21, 2024Assignee: Vector Vitale IP LLCInventors: Peter Novak, Max Temnik, Oleksandr Balakin
-
Publication number: 20240150280Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.Type: ApplicationFiled: November 1, 2023Publication date: May 9, 2024Applicant: Vector Vitale IP LLCInventors: Peter NOVAK, Maxim TEMNIKOV, Oleksandr BALAKIN
-
Publication number: 20230381347Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.Type: ApplicationFiled: August 9, 2023Publication date: November 30, 2023Applicant: Vector Vitale IP LLCInventors: Peter NOVAK, Max TEMNIK, Oleksandr BALAKIN
-
Patent number: 11827588Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.Type: GrantFiled: March 16, 2022Date of Patent: November 28, 2023Assignee: Vector Vitale IP LLCInventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
-
Patent number: 11779597Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.Type: GrantFiled: October 11, 2019Date of Patent: October 10, 2023Assignee: Vector Vitale IP LLCInventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
-
Patent number: 11730835Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.Type: GrantFiled: October 19, 2022Date of Patent: August 22, 2023Assignee: Vector Vitale IP LLCInventors: Peter Novak, Maxim V. Temnikov, Oleksandr Balakin
-
Publication number: 20230218665Abstract: An antibacterial composition that comprises as active compound at least one light isotope of an element selected from the group which consists of 1H, 12C, 16O, 14N, 39K, 24Mg, 64Zn, 85Rb, 28Si, 54Fe, 92Mo, 74Se, 58Ni, 70Ge, 52Cr, 63Cu, 50V, or combinations thereof, wherein the composition is enriched for the at least one light isotope. A method of treating and preventing bacterial diseases in humans and non-human animals by administering the composition. The use of the said composition in human and veterinary medicine for the prevention and treatment of diseases in humans and non-human animals and also as an antiseptic and disinfectant.Type: ApplicationFiled: January 23, 2023Publication date: July 13, 2023Applicant: Vector Vitale IP LLCInventors: Peter Y. NOVAK, Maxim V. TEMNIKOV, Oleksandr BALAKIN
-
Publication number: 20230210894Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.Type: ApplicationFiled: October 11, 2019Publication date: July 6, 2023Applicant: Vector Vitale IP LLCInventors: Peter NOVAK, Maxim TEMNIKOV, Oleksandr BALAKIN
-
Patent number: 11638721Abstract: An antibacterial composition that comprises as active compound at least one light isotope of an element selected from the group which consists of 1H, 12C, 16O, 14N, 39K, 24Mg, 64Zn, 85Rb, 28Si, 54Fe, 92Mo, 74Se, 58Ni, 70Ge, 52Cr, 63Cu, 50V, or combinations thereof, wherein the composition is enriched for the at least one light isotope. A method of treating and preventing bacterial diseases in humans and non-human animals by administering the composition. The use of the said composition in human and veterinary medicine for the prevention and treatment of diseases in humans and non-human animals and also as an antiseptic and disinfectant.Type: GrantFiled: December 5, 2018Date of Patent: May 2, 2023Assignee: Vector Vitale IP LLCInventors: Peter Y. Novak, Maxim V. Temnikov, Oleksandr Balakin
-
Patent number: 11596650Abstract: A method of preventing or treating type 2 diabetes comprising administering a therapeutically effective amount of 64Zn-enriched zinc.Type: GrantFiled: December 20, 2019Date of Patent: March 7, 2023Assignee: Vector Vitale IP LLCInventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
-
Publication number: 20230061538Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.Type: ApplicationFiled: October 19, 2022Publication date: March 2, 2023Applicant: Vector Vitale IP LLCInventors: Peter Y. Novak, Maxim V. Temnikov, Oleksandr Balakin
-
Publication number: 20230050325Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.Type: ApplicationFiled: October 19, 2022Publication date: February 16, 2023Applicant: Vector Vitale IP LLCInventors: Peter NOVAK, Maxim V. TEMNIKOV, Oleksandr BALAKIN
-
Patent number: 11559546Abstract: An antibacterial composition that comprises as active compound at least one light isotope of an element selected from the group which consists of 1H, 12C, 16O, 14N, 39K, 24Mg, 64Zn, 85Rb, 28Si, 54Fe, 92Mo, 74Se, 58Ni, 70Ge, 52Cr, 63Cu, 50V, or combinations thereof, wherein the composition is enriched for the at least one light isotope. A method of treating and preventing bacterial diseases in humans and non-human animals by administering the composition. The use of the said composition in human and veterinary medicine for the prevention and treatment of diseases in humans and non-human animals and also as an antiseptic and disinfectant.Type: GrantFiled: December 5, 2018Date of Patent: January 24, 2023Assignee: Vector Vitale IP LLCInventors: Peter Y. Novak, Maxim V. Temnikov, Oleksandr Balakin
-
Patent number: 11484550Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.Type: GrantFiled: December 7, 2020Date of Patent: November 1, 2022Assignee: VECTOR VITALE IP LLCInventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
-
Patent number: 11484610Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.Type: GrantFiled: November 22, 2019Date of Patent: November 1, 2022Assignee: VECTOR VITALE IP LLCInventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
-
Publication number: 20220220070Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.Type: ApplicationFiled: March 16, 2022Publication date: July 14, 2022Applicant: Vector Vitale IP LLCInventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
-
Patent number: 11286236Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.Type: GrantFiled: May 29, 2019Date of Patent: March 29, 2022Assignee: VECTOR VITALE IP LLCInventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin
-
Publication number: 20210322467Abstract: A method of treating or preventing a disease or condition caused (at least in part) by, or related to, a viral infection in a patient, comprising administering to said patient a pharmaceutical composition comprising, in certain embodiments, 64Zn-enriched zinc, at a therapeutically effective or a prophylactically effective dose for treating or preventing the disease or condition caused by the viral infection.Type: ApplicationFiled: April 14, 2021Publication date: October 21, 2021Applicant: Vector Vitale IP LLCInventors: Peter NOVAK, Maxim TEMNIKOV, Oleksandr BALAKIN
-
Publication number: 20210246104Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.Type: ApplicationFiled: May 29, 2019Publication date: August 12, 2021Applicant: Vector Vitale IP LLCInventors: Peter Novak, Maxim Temnikov, Oleksandr Balakin